The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
In recent years, the incidence of breast cancer has been increasing on an annual basis. Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.821663/full |
| _version_ | 1818942573328203776 |
|---|---|
| author | Mengmeng Lin Weiping Xiong Shiyuan Wang Yingying Li Chunying Hou Chunyu Li Guohui Li |
| author_facet | Mengmeng Lin Weiping Xiong Shiyuan Wang Yingying Li Chunying Hou Chunyu Li Guohui Li |
| author_sort | Mengmeng Lin |
| collection | DOAJ |
| description | In recent years, the incidence of breast cancer has been increasing on an annual basis. Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal antibody against HER-2. The most significant adverse effect of trastuzumab is cardiotoxicity, which has become an important factor in limiting the safe use of the drug. Unfortunately, the mechanism causing this cardiotoxicity is still not completely understood, and the use of preventive interventions remains controversial. This article focuses on trastuzumab-induced cardiotoxicity, reviewing the clinical application, potential cardiotoxicity, mechanism and discussing the potential interventions through summarizing related researches over the past tens of years. |
| first_indexed | 2024-12-20T07:13:35Z |
| format | Article |
| id | doaj.art-547dec31b57b4983bbe31b76f798e0d6 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-20T07:13:35Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-547dec31b57b4983bbe31b76f798e0d62022-12-21T19:48:50ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-01-01810.3389/fcvm.2021.821663821663The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer TreatmentMengmeng Lin0Weiping Xiong1Shiyuan Wang2Yingying Li3Chunying Hou4Chunyu Li5Guohui Li6National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Cardiology, Shanghai Putuo District Liqun Hospital, Shanghai, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaIn recent years, the incidence of breast cancer has been increasing on an annual basis. Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal antibody against HER-2. The most significant adverse effect of trastuzumab is cardiotoxicity, which has become an important factor in limiting the safe use of the drug. Unfortunately, the mechanism causing this cardiotoxicity is still not completely understood, and the use of preventive interventions remains controversial. This article focuses on trastuzumab-induced cardiotoxicity, reviewing the clinical application, potential cardiotoxicity, mechanism and discussing the potential interventions through summarizing related researches over the past tens of years.https://www.frontiersin.org/articles/10.3389/fcvm.2021.821663/fulltrastuzumabcardiotoxicitybreast canceradverse reactionrational drug use |
| spellingShingle | Mengmeng Lin Weiping Xiong Shiyuan Wang Yingying Li Chunying Hou Chunyu Li Guohui Li The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment Frontiers in Cardiovascular Medicine trastuzumab cardiotoxicity breast cancer adverse reaction rational drug use |
| title | The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment |
| title_full | The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment |
| title_fullStr | The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment |
| title_full_unstemmed | The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment |
| title_short | The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment |
| title_sort | research progress of trastuzumab induced cardiotoxicity in her 2 positive breast cancer treatment |
| topic | trastuzumab cardiotoxicity breast cancer adverse reaction rational drug use |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.821663/full |
| work_keys_str_mv | AT mengmenglin theresearchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT weipingxiong theresearchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT shiyuanwang theresearchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT yingyingli theresearchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT chunyinghou theresearchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT chunyuli theresearchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT guohuili theresearchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT mengmenglin researchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT weipingxiong researchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT shiyuanwang researchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT yingyingli researchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT chunyinghou researchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT chunyuli researchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment AT guohuili researchprogressoftrastuzumabinducedcardiotoxicityinher2positivebreastcancertreatment |